Our Friday video this week is taken from our recent ‘Celebrating UK Bioscience’ campaign.
Duchenne muscular dystrophy (DMD) is a fatal muscle-wasting condition, caused by the lack of a protein called dystrophin. Summit Therapeutics, a biotechnology company based in Oxfordshire is developing a potential treatment approach, known as utrophin modulation, to slow or stop disease progression.
Watch the video to hear from Summit Therapeutics, charity Muscular Dystrophy UK and Charmaine Twine, ambassador for MDUK whose two sons Josh and Ethan have DMD.
Learn more about the ‘Celebrating UK Bioscience’ campaign here.
Do you have a video you would like the sector to see? Contact us.